Advanced Search

Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular imaging 2011 June;55(3) > The Quarterly Journal of Nuclear Medicine and Molecular imaging 2011 June;55(3):265-79

ISSUES AND ARTICLES   MOST READ   eTOC

CURRENT ISSUETHE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

A Journal on Nuclear Medicine and Molecular Imaging

A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 1,724

Frequency: Quarterly

ISSN 1824-4785

Online ISSN 1827-1936

The Quarterly Journal of Nuclear Medicine and Molecular imaging 2011 June;55(3):265-79

CLINICAL OUTCOMES OF AMYLOID IMAGIN IN CROSS SECTIONAL AND LONGITUDINAL STUDIES 

    REVIEWS

Amyloid imaging as a surrogate marker in clinical trials in Alzheimer’s disease

Scheinin Noora M. 1, Scheinin M. 2, Rinne J. O. 1

1 Turku PET Centre, University of Turku and, Turku University Hospital, Turku, Finland;
2 Unit of Clinical Pharmacology, Department of Pharmacology, Drug Development and Therapeutics, University of Turku, TYKSLAB, Turku, Finland

New treatments against Alzheimer’s disease (AD) may be just around the corner. A common approach in developing these disease-modifying treatments is to target beta-amyloid (Aβ). Aβ is excessively present in the AD brain and it likely starts to accumulate long before clinical symptoms become apparent. As Aβ is hypothesized to be the causative agent in the pathophysiological cascade leading to progressive neurodegeneration in AD, efforts to e.g. prevent its formation, to promote its clearance from brain tissue, and to inhibit its toxicity, are warranted. This quest for an effective AD treatment needs valid biomarker outcome measures, for instance because clinical benefit takes long to present itself and is difficult to measure, and also because treatment would likely be most efficacious if administered already before symptoms occur. In vivo amyloid imaging has evolved in the past decade to be a feasible means to monitor brain Aβ deposits in the human brain. It effectively differentiates AD patients from healthy age-matched controls, and also shows promise in the early, even presymptomatic, detection of AD. Amyloid imaging will likely also broaden and deepen our understanding of AD and other neurodegenerative disorders. It could prove valuable e.g. in subject selection and stratification for clinical trials, in safety and proof-of-concept assessments, and in monitoring of treatment effects. This article aims to review the motives, prerequisites, potential, and challenges of using amyloid imaging as a surrogate marker in clinical therapeutic trials in AD.

language: English


FULL TEXT  REPRINTS

top of page